Abstract:Objective To systematically investigate the prognosis of patients with chronic heart failure (CHF) treated with sacubitril/valsartan sodium.Methods Relevant studies were searched in databases CNKI,VIP,Wanfang,Pubmed,Web of Science,and Cochrane library until December 20,2020.Endnote software was used to screen out duplicate literatures and read literature abstract.Revman 5.3 software was used for bias risk assessment,sensitivity analysis,and subgroup analysis.Results A total of 9 studies (13 217 cases) were included in this analysis.Meta-analysis showed that the rehospitalization rate of the sacubitril/valsartan sodium group for treatment of chronic heart failure ［OR=0.77,95%CI(0.71,0.84),P＜0.01］,cardiovascular mortality ［OR=0.81,95%CI(0.73,0.90),P＜0.01］,all-cause mortality ［OR=0.86,95%CI(0.78,0.94),P＜0.01］ were lower than those of ACEI/ARB group.There was no significant difference in adverse cardiovascular events between two groups (P=0.33).conclusions Sacubitril/valsartan sodium can effectively reduce the rehospitalization rate,cardiovascular mortality and all-cause mortality in patients with chronic heart failure,but no significant reduction in cardiovascular adverse events has been observed.